NPI: 1619079647 · LA PLACE, LA 70068 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 09/01/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 09/01/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 4,280 | $9K |
| 2019 | 4,602 | $6K |
| 2020 | 4,124 | $4K |
| 2021 | 377 | $11K |
| 2022 | 676 | $40K |
| 2023 | 722 | $79K |
| 2024 | 830 | $94K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 2,068 | 384 | $222K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 9,473 | 591 | $20K |
| J1270 | Injection, doxercalciferol, 1 mcg | 239 | 26 | $13.00 |
| A4657 | Syringe, with or without needle, each | 1,902 | 801 | $0.00 |
| 83550 | 229 | 207 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 51 | 41 | $0.00 |
| 82728 | 211 | 193 | $0.00 | |
| 83970 | 327 | 286 | $0.00 | |
| 85048 | 441 | 410 | $0.00 | |
| 85041 | 441 | 410 | $0.00 | |
| 83540 | 229 | 207 | $0.00 |